Four biotech start-ups selected for new project: The Hive

Participants have access to Elsevier’s tools to develop drugs for unmet medical needs


Working in drug discovery and development is a race to the finish line; the earliest steps are crucial and may determine whether the world gets a life-altering cure. From the outset, chemists, biologists and other R&D professionals need access to networks of scientific knowledge and research, enabling them to innovate, make key discoveries, and avoid late stage failures.

The Hive, a project for biotech and pharmaceutical start-up firms, was designed to empower this stage of research and generate stories that offer lessons on how R&D teams can overcome the bottlenecks and challenges that arise in the process.

The Hive is zeroing in on the work of start-up companies because such organizations are at the heart of innovation in the pharmaceutical biotech industry. By sharing the stories of innovative start-ups working in early stage drug development, The Hive aims to serve as a catalyst for the wider community to learn more from one another. It will showcase the diverse paths to pharmaceutical innovation.

Four start-ups have been selected to participate in The Hive.

  • Arctic Pharma AS is developing anti-cancer drugs by exploiting the “sweet tooth” of cancer cells and their peculiar metabolic features. Key enzymes that are upregulated in cancer cell metabolism are targeted with inhibitors designed at Arctic Pharma. This supports Arctic Pharma’s development of new pharmaceuticals to combat cancer that exhibit few side effects.
  • Myelo Therapeutics is developing treatments in areas of high unmet medical needs. Its lead compound, Myelo001, is an orally applied small molecule. MyeloConcept, a phase IIa clinical trial, currently investigates the efficacy of Myelo001 in reducing the occurrence of Chemotherapy-Induced Neutropenia (CIN), a side effect of cytotoxic chemotherapy that can delay treatment.
  • Reset Therapeutics is a discovery-stage biopharma company developing first-in-class approaches to treating diseases by restoring the body’s natural 24-hour, or circadian, rhythms. Reset’s pipeline includes new chemical entities designed to treat Cushing’s disease, type-2 diabetes and other metabolic disorders and narcolepsy and other disorders associated with excessive daytime sleepiness.
  • Rubius Therapeutics, founded by Flagship VentureLabs, is using breakthrough science to develop an entirely new class of therapy. Red-Cell Therapeutics (RCTs) have the potential to treat a wide array of diseases, including rare genetic disorders, metabolic conditions, cancer, autoimmune and infectious diseases.

“The goal of The Hive is to highlight the incredible innovation taking place outside the walls of traditional pharma companies, and to celebrate the important role that small biotech start-ups play in the origin of drug discoveries,” said Alexander Van Boetzelaer, Managing Director of Elsevier R&D Solutions. “These companies are typical of the cutting-edge research happening in the biotech industry, with huge potential to drive successful pharmaceutical outcomes and improve the lives of patients. We look forward to sharing their stories.”

To support their work, these firms are receiving complimentary access (along with training) to ScienceDirect and Scopus and Elsevier R&D’s life science solutions Reaxys, Pathway Studio, Pharmapendium and Embase. These are used by leading pharma companies to search vast amounts of data to find key information for drug discovery and development.

Claudia A. McDonald Bøen, PhD“Our mission is to make Arctic Pharma a leader in cancer therapies that are environmentally friendly and have few side effects,” said Dr. Claudia A. McDonald Bøen, CEO of Arctic Pharma.  “Access to Elsevier’s suite of programs will allow us to achieve this aim. As a small start-up company, the opportunity to be part of The Hive is significant. It will give us access to trustworthy data that will help us make better informed decisions on lead compound selections, and increase our productivity and scientific progress by reducing the time we spend searching data to find everything that is relevant.”

“Elsevier’s mission is to fuel discovery, drive innovation and improve healthcare,” said Tim Hoctor, VP of Life Sciences Solution Services at Elsevier. “Projects like The Hive can empower the innovative organizations and individuals that are working to create miracles for those suffering from some form of illness.”

The Hive participantsTo follow The Hive

By following The Hive, you’ll hear directly from the four participating companies while supporting and learning from their research projects. To stay abreast of opportunities and learn more about the work, scientific discoveries and challenges of the four participants – and share your own experiences – visit and sign up for updates.


Written by

Claudine Berti

Written by

Claudine Berti

Claudine Berti, Director of Digital Marketing for R&D Solutions at Elsevier, is a highly creative digital marketer and skilled strategist with a history of transforming strategic plans into actionable and executable campaigns and programs. She has extensive experience in B&B marketing; particularly in the areas of digital strategy, customer insights and analytics. Claudine currently leads digital marketing programs (such as, web design and development, SEM, social media, video production and blogs) designed to increase awareness and generate demand for Elsevier’s R&D Solutions.


comments powered by Disqus